NCT02000102
Completed
Not Applicable
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
ConditionsDiabetic Macular Edema
InterventionsIntravitreal Injection of Aflibercept
Overview
- Phase
- Not Applicable
- Intervention
- Intravitreal Injection of Aflibercept
- Conditions
- Diabetic Macular Edema
- Sponsor
- Stanford University
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Visual Acuity
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -
Exclusion Criteria
- Not provided
Arms & Interventions
Diabetic Macular Edema Patients Switched to Aflibercept
Intervention: Intravitreal Injection of Aflibercept
Outcomes
Primary Outcomes
Visual Acuity
Time Frame: 1 year
Secondary Outcomes
- Central Subfield Thickness on Optical Coherence Tomography(1 year)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Aflibercept for Diabetic Macular Edema In Real-life Practice in GREeceDiabetic Macular EdemaNCT05683912University of Athens100
Completed
Phase 4
Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)Diabetic Macular EdemaNCT04087746Minia University400
Completed
Phase 4
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular EdemaDiabetic Macular EdemaNCT02441907Unity Health Toronto16
Unknown
Phase 4
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective StudyDiabetic Macular EdemaNCT02651168Unity Health Toronto50
Completed
Phase 4
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular EdemaRetinal DiseasesNCT02646670Instituto de Olhos de Goiania20